Skip to main content
| News

Holmusk opens new office in Basel

18.01.2021

Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis. Holmusk has placed a focus on the treatment of mental illnesses.

Nawal Roy, CEO of Holmusk (img: Holmusk)

Holmusk has recently moved into a new location at the Novartis Campus of the Switzerland Innovation Park Basel Area. The life sciences company develops data-driven digital therapies to treat a variety of disorders. Its focus is on mental and neurological illnesses, additionally Holmusk is active in the areas of cardiovascular and renal diseases, as well as diabetes.

The new office in Basel represents Holmusk’s seventh international office and second in Europe. According to Stefan Suter, Head of Holmusk Europe, staffing was a key consideration in the choice of Basel as a location: “In Basel we find multilingual, specialized talent from fresh graduates to seasoned professionals to be part of the data-driven revolution in healthcare”. In addition to current and future employees, the companies already located in Basel were also a significant pull factor for Holmusk. “Basel, with its large ecosystem of global leaders in life sciences offers multiple partnership opportunities and allows direct access to expand business into Germany or France”, explains Nawal Roy, CEO of Holmusk.

Holmusk is planning to build the world’s largest platform for what is known as real-world evidence (RWE), in which data from clinical practice is used to develop treatments. Holmusk has already been active in this area for five years, while the company also managed to successfully raise a total of 21.5 million US dollars in 2020 as part of a Series A financing round.

Switzerland Innovation Park Basel Area is operated by Basel Area Business & Innovation. The investment and innovation promotion agency also supported Holmusk during the process of establishing its business in the region.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Basel still the most attractive small city for business in Europe
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Ariceum Therapeutics establishes subsidiary in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
RocketVax raises fresh capital
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

RocketVax raises fresh capital

The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...

Read More
Clinerion is now part of Citeline
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion is now part of Citeline

Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...

Read More
KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.